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Neutrophil antimicrobial peptide -defensin
causes endothelial dysfunction in porcine
coronary arteries
Panagiotis Kougias, MD, Hong Chai, MD, PhD, Peter H. Lin, MD, Qizhi Yao, MD, PhD,
Alan B. Lumsden, MD, and Changyi Chen, MD, PhD, Houston, Tex
Background:Defensins are cysteine-rich cationic polypeptides released from neutrophils that exhibit powerful antimicro-
bial activities. Because inflammation, including neutrophil infiltration and release of defensins, may play an important
role in atherosclerosis and other vascular diseases, we determined whether -defensin could cause endothelial dysfunc-
tion, a major initial event of atherosclerosis, in porcine coronary arteries.
Methods: Porcine coronary arteries were sliced into 5-mm rings and treated with different concentrations of human
recombinant -defensin for 24 hours. Vasomotor reactivity was studied by using a myograph system. Levels of
superoxide anion were detected by the lucigenin-enhanced chemiluminescence method. Endothelial nitric oxide synthase
(eNOS) messenger RNA (mRNA) and protein levels were determined by real-time polymerase chain reaction and
immunohistochemistry analysis, respectively.
Results: Endothelium-dependent relaxation in response to bradykinin was significantly reduced by 40% for the rings
treated with 1500 nM of -defensin compared with controls (P < .05). Vessel contractility in response to the
thromboxane A2 analogue U46619 and endothelium-independent relaxation in response to sodium nitroprusside were
not affected with defensin treatment. In addition, the superoxide anion level at the endothelial layer of porcine coronary
artery rings was significantly increased by 80% in the defensin-treated (1500 nM) vessels compared with controls (P <
.05). Furthermore, the eNOS mRNA levels in endothelial cells isolated from the cultured rings treated with defensin
(1500 nM) were significantly decreased by 27% compared with controls (P < .05). Immunoreactivity of eNOS in the
defensin-treated vessel rings was also substantially reduced.
Conclusions: Defensin reduces the endothelium-dependent vasorelaxation. This effect is associated with increased
superoxide radical production and decreased eNOS expression in porcine coronary arteries.
Clinical Relevance: Inflammation is an important mechanism of atherosclerosis and other vascular diseases. The roles and
interactions of biomediators released from inflammatory cells are not fully understood, however. This study provides new
information about effects and potential molecular mechanisms of a major neutrophil releasing factor, -defensin, on
endothelial dysfunction of porcine coronary arteries. Thus, targeting -defensin and its associated molecular mechanisms
may become a new strategy to prevent vascular diseases. ( J Vasc Surg 2006;43:357-63.)Atherosclerosis is a disease process that starts in fetal
life,1 progresses over decades under the influence of genetic
and environmental factors, and is associated with a huge
financial and social cost in modern societies.2 Retention of
low-density lipoproteins within the walls of blood vessels3
and the development of an intense local inflammation
during the response of the endothelial cells to a broad range
of noxious stimuli4,5 are among the most popular theories
that attempt to unify observational experimental data with
the clinical characteristics of the disease. It is accepted that
the presence of endothelial dysfunction, regardless of etiol-
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Several lines of evidence show that inflammatory cells
are responsible for the impairment of endothelial cell func-
tions in atherosclerosis via the release of a number of media-
tors.6,7 It is also known that anti-inflammatory agents such as
aspirin or steroids can attenuate the inflammation-induced
endothelial dysfunction.8 Neutrophils a r e present in high
numbers in the serum of atherosclerotic individuals and
within atherosclerotic plaques.9-11 Naturally occurring an-
timicrobial peptides stored in the azurophilic granules of
neutrophils are released during infection and constitute an
essential component of the innate immunity, but they have
also been found in large quantities within atheromatous
plaques in the cerebral and coronary circulation.12,13 The
role of these peptides has now broadened from simply
endogenous effectors of the innate immunity to multifunc-
tional mediators that can modify the local inflammatory
response.14
Among these peptides, defensins constitute a class of
cysteine-rich cationic polypeptide antibiotics that have
been isolated from mammals, insects, and plants15 and have
been reported to possess several proatherogenic properties.16
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is present in large quantities in atheromatous lesions, can
induce endothelial dysfunction. To test this hypothesis, we
investigated the effects of defensin in a porcine coronary artery
model. Potential mechanisms that explain the defensin-
induced endothelial dysfunction via altered endothelial ni-
tric oxide synthase (eNOS) levels or nitric oxide depletion
by superoxide radicals were also studied. Our results sug-
gest that -defensin interferes with vasomotor reactivity
and further supports the role of neutrophils in atheroscle-
rosis.
METHODS
Chemicals and reagents. Thromboxane A2 analogue
U46619 (9,11-Dideoxy-11,9-epoxymethanoprostaglandin
F2), bradykinin, sodium nitroprusside (SNP), phosphate-
buffered saline (PBS) solution, and Tri-reagent kit were
obtained from Sigma Chemical Co (St. Louis, Mo). Hu-
man -defensin, which is composed of three closely related
gene products and is also referred to as human neutrophil
peptides 1-3, was obtained from Phoenix Pharmaceuticals
(Belmont, Calif). Lucigenin was obtained from Molecular
Probes (Eugene, Ore). Dulbecco’s modified Eagle’s me-
dium (DMEM) was obtained from Life Technologies, Inc
(Grand Island, NY). Antibiotic-antimycotic solution was
obtained from Mediatech Inc (Herndon, Va). iScript
cDNA Synthesis Kit and the iQ SYBR Green SuperMix Kit
were obtained from Bio-Rad Laboratories (Hercules,
Calif). Antibody against human eNOS was obtained from
BD Transduction Laboratories (Lexington, Ky). The bio-
tinylated horse antimouse immunoglobulin G and avidin-
biotin complex kit were from Vector Labs (Burlingame,
Calif).
Tissue harvest and culture. Fresh porcine hearts were
harvested from farm pigs (6 to 8 months old) at a local
slaughterhouse. The hearts were immediately rinsed with
sterile PBS, the aortic arch and coronary arteries were
perfused with cold PBS, and each was stored in ice-cold
PBS for transport back to the laboratory. The right coro-
nary arteries from the hearts were dissected, the perivascular
connective tissue was removed, and the arteries were di-
vided into 5-mm rings to be used in the experiments.
Several rings from each heart were assigned into groups
that included controls treated with only dimethylsulfoxide
(DMSO), and those treated with defensin at 15, 150, and
1500 nM. The rings were incubated in DMEM with de-
fensin or vehicle (DMSO) at 37°C and 5% carbon dioxide
for 24 hours. An antibiotic-antimycotic solution (0.5%) was
added to the tissue culture medium for all experiments.
Myograph analysis. The myograph tension system
used in our laboratory has previously been described.17,18
After being cultured in the medium for 24 hours, rings
were suspended between the wires of the organ bath cham-
ber (Multi myograph system 700MO; Danish Myo Tech-
nology, Aarhus, Denmark) in 6 mL of Krebs solution,
maintained at 37°C, and were continuously oxygenated.
Rings were slowly subjected to a predetermined tension of
30 millinewton (mN) and allowed to equilibrate for 25 to30 minutes. After equilibration, each ring was precon-
tracted with 20 L of thromboxane A2 analogue U46619
(107 M). After 60 to 90 minutes of contraction, a relax-
ation dose-response curve was generated by adding 60L of
five cumulative additions of the endothelium-dependent
vasodilator bradykinin (109, 108, 107, 106, and 105
M) every 3minutes. At the end, 60L of SNP (106M) was
added into the organ bath, and endothelium-independent
vasorelaxation was recorded. Contractility and percentage of
relaxation were calculated based on the tension changes.
Detection of superoxide anion. Levels of superoxide
anion produced by endothelial cells were detected by using
the lucigenin-enhanced chemiluminescence method with a
Sairius Luminometer and FB12 software (Berthold Detec-
tion System GmbH, Pforzheim, Germany). Vessel rings
incubated with the medium only (controls) and the rings
treated with 1500 nM of defensin were studied. The rings
were cut open longitudinally and trimmed into approxi-
mately 5 5-mm pieces. They were then rinsed briefly in a
modified Krebs N-(2-hydroxyethyl) piperazine-N’-(2-
ethanesulphonic acid)(HEPES) buffer solution.17,18
After the solutions were gently mixed, the vessel seg-
ments were placed with the endothelium side facing down
in the tubes to record signals from the endothelial layer.
Time-based reading of the luminometer was recorded by
using the FB12 software. The data were obtained in relative
light units per second (RLU/sec) for each sample and were
averaged between 5 and 10 minutes. Values of blank tubes
containing the same reagents were subtracted from those of
their corresponding vessel samples. The area of each vessel
segment was measured with a caliper and used to normalize
the data for each ring sample. Final data are presented as
RLU/sec/mm2.
Real-time polymerase chain reaction. Porcine coro-
nary artery rings were incubated with different concentra-
tions of defensin for 24 hours, and the endothelial cells
were scraped off the vessel intima and processed using
Tri-Reagent as previously described.17,18 Briefly, the RNA
from rings was resuspended in 20 L of RNase-free water.
Complimentary DNA (cDNA) was generated by reverse
transcription from mRNA using the iScript cDNA Syn-
thesis Kit. The iQ SYBR Green SuperMix Kit was used
for real-time polymerase chain reaction (PCR). Porcine
eNOS and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) primers were designed using Beacon De-
signer (Premier Biosoft, Palo Alto, Calif). Sample cycle
threshold (Ct) values were determined from plots of
relative fluorescence units (RFU) vs PCR cycle number
during exponential amplification so that sample measure-
ment comparisons were possible. The eNOS gene expres-
sion in each sample was calculated as 2^(40–Ct) and fur-
ther normalized to GAPDH expression as 2^(Ct[GAPDH]–
Ct[eNOS]).
eNOS immunohistochemistry. Treated rings were
fixed in 10% neutral buffered formalin and embedded in
paraffin. Cross-sections were stained with a monoclonal
antibody against human eNOS (1:1000) by using the
avidin-biotin complex immunoperoxidase procedure.
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BX41 microscope (Olympus USA, Melville, NY). Images
were captured with an attached SPOT-RT digital camera
and software (Diagnostic Instruments, Sterling Heights,
Mich).
Statistical analysis. A total of 18 hearts were har-
vested and used for this study. For each heart, the right
coronary artery was isolated and cut into multiple 5-mm
rings. The data of several coronary artery rings from each
heart were averaged and represented as one data point for
statistical analysis. Thus, the sample size is the number of
hearts used. Among 18 hearts, 9 hearts were used for
myographic analysis and the rings from each heart were
randomly assigned to several groups of experiments. An
additional nine hearts were used for real-time PCR (n 6)
and for superoxide anion detection and immunohisto-
chemistry staining (n  3). Statistical analysis was per-
formed on the Data Analysis tool of the Microsoft Office
2000 Excel program (Microsoft Inc, Redmond, Wash.).
Data were expressed as mean SE. Significant difference of
data between control and treated groups was determined
by paired Student’s t test (two-tail). Comparison of vasore-
laxation in response to a series of concentrations of brady-
kinin among the four groups was analyzed with the single-
factor analysis of variance test. P  .05 was considered
statistically significant.
RESULTS
Defensin impairs endothelium-dependent vasore-
laxation in porcine coronary arteries. Porcine coronary
artery rings were cultured for 24 hours with a clinically
relevant concentration of 15 (n 6), 150 (n 5), or 1500
nM (n  9) of defensin and then subjected to physiologic
contraction (U46619) as well as endothelium-dependent
(bradykinin) and endothelium-independent (SNP) relax-
ation. In response to U46619, the contraction of the vessel
rings was changed in a random manner unrelated to the
concentration of defensin and was not statistically signifi-
cant with that of controls (Fig 1). In response to bradykinin
at 105 M, the endothelium-dependent relaxation com-
pared with controls was reduced by 40% (P  .05) and 12%
(P  .05) for the rings treated with 1500 and 150 nM of
defensin, respectively. Rings treated with 15 nM of
defensin demonstrated relaxation equalling that of con-
trols (Fig 2). The endothelium-independent vasorelax-
ation in response to SNP was minimally changed in a
random and statistically insignificant manner (P  .05)
(Fig 3).
Defensin increases superoxide anion production in
porcine coronary arteries. Oxidative stress is a central
event in the development of endothelial dysfunction and
vascular injury. To determine whether this mechanism is in-
volved in defensin-induced vasomotor dysfunction, superox-
ide anion production was analyzed by a lucigenin-enhanced
chemiluminescence assay (n 3 for each group). The super-
oxide anion levels of the endothelial layer were significantly
increased by 80% for the rings treated with defensin (1500
nM) compared with controls (P  .05) (Fig 4).Defensin reduces eNOS expression in porcine cor-
onary arteries. Todeterminewhether eNOSexpressionwas
correlated with the reduction of endothelium-dependent va-
sorelaxation after treatment with defensin, porcine coronary
artery rings were incubated with defensin (0, 150, and 1500
nM) (n  6 for each group). The eNOS levels were then
calculated using real-time PCR and were found to be
significantly reduced by 27% in the rings treated with 1500
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Fig 1. Effect of defensin on the contractility of porcine coronary
arteries. Pig coronary artery rings were cultured with the medium
dimethylsulfoxide (as control) or treated with -defensin (15, 150,
or 1500 nM) for 24 hours. Contraction of the vessel rings was
achieved with addition of thromboxane A2 analogue U46619
(107 M). There was no specific pattern in the changes in contrac-
tility between rings treated with defensin and controls (n 9) (P
.05). Data are shown as mean  SE.
 )1( lortnoC
nisnefeD Mn 51 )2(
nisnefeD Mn 051 )3(
nisnefeD Mn 0051 )4(
)4( *
)3(
)2()1(
0
01
%
 o
f 
R
el
ax
at
io
n 02
03
04
05
06
07
08
0 01 9- 01 7-01 8- 01 6- 01 5-
ninikydarB C tartnecno ( noi M)
Fig 2. Effect of defensin on the endothelium-dependent relax-
ation of porcine coronary arteries. Precontracted vessels exposed to
different defensin concentrations were tested for endothelium-
dependent relaxation by the addition of bradykinin (109 to 105
M). The artery treated with -defensin (1500 nM) showed a
statistically significant reduction in relaxation by 40% compared
with controls (n 9) (*P .05). Rings incubated with -defensin
(150 nM) demonstrated a 12% reduction in relaxation compared
with controls. No change in the endothelium-dependent relax-
ation was seen in the rings treated with -defensin (15 nM). Data
are expressed as mean  SE.nM compared with controls (P  .05) (Fig 5). Immuno-
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porcine coronary artery rings using the avidin-biotin com-
plex immunoperoxidase procedure. Immunoreactivity of
eNOS of the endothelial cells of defensin-treated vessel
rings was substantially reduced compared with controls
(Fig 6).
DISCUSSION
To our knowledge, this is the first study to demonstrate
that -defensin can cause endothelial dysfunction of por-
cine coronary arteries in association with increased super-
oxide anion production and decreased eNOS expression.
Defensins are naturally occurring antibiotic polypep-
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Fig 3. Effect of defensin of the endothelium-independent relax-
ation of porcine coronary arteries. Precontracted rings (n  9)
were tested for endothelium-independent relaxation in response to
sodium nitroprusside (106 M) after exposure to three different
defensin concentrations. The noticed change in relaxation was
random and not statistically significant (P  .05). Data are ex-
pressed as mean  SE.
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Fig 4. Effect of defensin on superoxide anion production in
porcine coronary arteries. Superoxide anion levels in porcine cor-
onary arteries were tested with lucigenin-enhanced chemilumines-
cence assay. The data were normalized with the area (mm2) of the
ring, and are expressed as relative light units (RLU/sec/mm2).
Defensin at 1500 nM increased the superoxide anion production
by 80% compared to controls (n  3) (*P  .05). Data are
expressed as mean  SE.tides that are abundant in nature and exhibit remarkableantiviral, antibacterial, and antifungal activities.15 In hu-
mans, -defensin has a length of 29 to 35 amino acids and
is located in neutrophils and in the Paneth cells of the small
intestine, where it is stored as pre-propeptides.19 Defensins
are incorporated into the cell membrane of prokaryotic
organisms during the process of phagocytosis, disrupt ion
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Fig 5. Effect of defensin on the endothelial nitric oxide synthase
(eNOS) messenger (mRNA) levels of porcine coronary arteries.
The rings were incubated with defensin (150 nM or 1500 nM) for
24 hours. Real-time polymerase chain reaction was used to assess
eNOS mRNA expression. Addition of defensin (1500 nM) re-
duced the eNOS mRNA expression by 27% compared with con-
trols (*P .05). The smaller dose of defensin (150 nM) incurred a
mild decrease in the levels of eNOSmRNA expression (n 6 for all
groups) (P  0.05). Data are expressed as mean  SE. GAPDH,
Glyceraldehyde-3-phosphate dehydrogenase.
Fig 6. Effect of defensin on the endothelial nitric oxide synthase
(eNOS) immunoreactivity of porcine coronary arteries. Avidin-
biotin complex immunoperoxidase procedure followed by DAB
reaction was used to detect eNOS protein levels in both (A)
control and (B) defensin-treated vessels. High dose defensin
(1500 nM) treatment (B) substantially reduced eNOS immunore-
activity (arrows) compared with controls (A) (n  3). Original
magnification 400.fluxes, and promote cell lysis.20 In addition to their antimi-
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link among lipid accumulation in the vessel wall, local
inflammation, and endothelial cell perturbation. Defensins
participate in the lipoprotein uptake and degradation in the
vessel wall,12,21,22 interfere with vascular smooth muscle
cell functions,23 possess antifibrinolytic activity,24,25 and
regulate angiogenesis.26
The plasma concentration of defensin is 15 nM in
healthy subjects, but levels as high as 50,000 nM have been
recorded in patients with sepsis or bacterial meningitis.27
For our experiments, we selected a range of doses (15, 150,
and 1500 nM) that mimic conditions of health and disease.
Impaired vasorelaxation in response to pharmaco-
logic agents is a known indicator of vascular dysfunc-
tion.28 In current study, human  -defensin significantly
impaired endothelium-dependent vasorelaxation in a
dose-dependent manner. For the arteries incubated with
15, 150 and 1500 nM of defensin, the decrease in
bradykinin-induced vasorelaxation compared with con-
trols was 0%, 12%, and 40%, respectively, indicating
defensin-induced endothelial dysfunction. It is notewor-
thy that in physiologic doses, defensin had no impact on
endothelial cell function, a fact consistent with its role as
a host-friendly agent of immune surveillance. Defensin
had no effect on the SNP-induced vasorelaxation, indi-
cating that its activity is largely endothelium-mediated.
Since defensin is dissolved in DMSO solution, we used
an equal amount of DMSO as a vehicle control (negative
control) in the experiments. For future studies, random-
sequence cysteine-rich cationic polypeptidemay be used for
a much stronger negative control for defensins.
Another issue is the activity of human -defensin on
other species. Human -defensin has biologic effects on rat
vascular smooth muscle cells,29 but it has not been tested
on porcine cells or tissues. Information about porcine
-defensin (genes and sequences) is also not available at this
time. Our current study clearly demonstrates that human
-defensin does affect porcine coronary arteries. However,
it is not clear whether the activity and potency of human
-defensin for human cells or tissues are different for por-
cine cells and tissues. Further investigations with human
cells or tissues are warranted to address this important issue.
In recent years, we have established and characterized
the in vitro culture model of porcine coronary artery rings
for myograph analysis. Specially, endothelium-dependent
vasorelaxation can be analyzed with a challenge of bradyki-
nin, a potent vasodilator that acts through endothelial B2
kinin receptors to stimulate the release of nitric oxide
through eNOS activation.30 We have used this model to
study the effects of several clinical risk factors or molecules
on endothelial functions. For examples, homocysteine (50
M), resistin (40 ng/mL), progesterone (1  106 g/L),
HIV Tat (107 M), ritonavir (15 M), and lysophosphati-
dylcholine (25 M) significantly reduced the endothelium-
dependent vasorelaxation of porcine coronary artery rings
by 30%,31 30%,18 38%,32 46%,33 59%,17 and 81%,34 respec-
tively. In current study, human -defensin (1500 nM)
significantly reduced endothelium-dependent vasorelax-ation by 40% compared with controls. These molecules
may independently contribute to vascular disease forma-
tion.
Imbalance in the production and catabolism of reactive
oxygen species (ROS) generated during aerobic metabo-
lism is known to lead to oxidative stress and contributes to
vascular disease via a variety of mechanisms that include a
state of continuous nitric oxide consumption and deple-
tion,35,36 intracellular alkalinization,37 and regulation of
gene transcription.38 In our study, an 80% increase of
superoxide anion production was shown in the defensin-
treated rings compared with controls, indicating that oxi-
dative stress may be one of the predominant mechanisms in
defensin-induced endothelial dysfunction.
A central event in the vascular cell homeostasis involves
the fine regulation of nitric oxide bioavailability. Nitric
oxide is generated by eNOS and is a potent vasodilator with
multiple additional cardiovascular functions.39 eNOS is
important in atherosclerotic disease.40,41 Patients with
eNOS polymorphism that reduces enzymatic activity ex-
hibit higher rates of myocardial events.42 We believe our
data show that the changes in endothelium-dependent
relaxation may also be due to the decrease in eNOS expres-
sion. Indeed, the real-time PCR data showed a significant
decrease of eNOS mRNA expression in defensin-treated
vessel rings and agreed with data obtained from the immu-
nohistochemistry studies. Real-time PCR is a very sensitive
method to detect mRNA levels for many genes. Two most
important quality control procedures are primer design of
the gene of interest (specific) and a housekeeping gene (no
change). We have developed these high standards for por-
cine eNOS and have published several studies related to
eNOS downregulation.17,18,31-34
We believe that any statistically significant difference of
mRNA downregulation normalized to GAPDHwill have a
biologic significance of eNOS-mediated functions. In cur-
rent study, a 27% reduction of eNOS mRNA levels in
defensin-treated (1500 nM) vessels compared with control
vessels may account for the defensin-induced inhibition of
endothelium-dependent vasorelaxation. eNOS immunore-
activity was reduced in defensin-treated (1500 nM) vessels
by gross observation of color intensity. However, quantita-
tion of eNOS immunoreactivity was not performed owing
to technique difficulties and variability of staining. More
reliable quantitative methods, such as Western blot for
eNOS protein, may be warranted for studying the effect of
human defensins on eNOS expression in porcine coronary
arteries. These findings, together with the functional data
obtained from myograph analysis, suggest a potential
mechanism of defensin-induced damage to the endothelial
cells via decreased eNOS expression and nitric oxide bio-
availability.
Defensins are known to interfere with lipoprotein
metabolism in endothelial cells and smooth muscle cells,
favoring the intra- and extracellular lipoprotein (a) and
low-density lipoprotein accumulation.12,21,22 Subse-
quent oxidation of these lipids has well known detrimen-
tal effects on the vasomotor properties of the vessel.43,44
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the vasculature is an indirect effect via altered lipid
metabolism. In our model, -defensin impaired endo-
thelium-dependent relaxation in the absence of lipids,
indicating a direct interaction at the endothelial cell
level. Nassar et al23 have shown that  -defensin binds to
the low-density lipoprotein receptor-related protein/
2macroglobulin receptor, inhibits the mobilization of
intracellular calcium (Ca		) promoted by phenyleph-
rine, and ultimately interferes with the phenylephrine-
induced smooth muscle cell contraction in denuded rat
aortic rings. The authors, however, noted that defensin
alone did not have any effect on Ca		mobilization or
contractility. The presence of intact endothelium seems
to be a prerequisite for the manifestation of a direct
defensin activity on vascular tone.
The precise role of defensins in the pathogenesis of
endothelial dysfunction appears to be very intriguing, yet
poorly defined. Defensins provide a unique link between
two coexisting phenomena of arterial wall inflammation
and lipid accumulation. Further study is necessary to deci-
pher its role on atherosclerosis. For instance, defensin re-
ceptors have been identified on human umbilical vein en-
dothelial cells and smooth muscle cells.21,23,25 However,
the binding specificity, the downstream molecular events
triggered by the defensin ligand, and the functional signif-
icance of the defensin-induced intracellular signal transduc-
tion pathways are not well understood. In addition, the
significance of these observations in vivo has not been
proved yet, and it is worth further investigation. Finally,
little is known about factors that regulate defensin activity
and influence its local concentration in the arterial wall.
CONCLUSION
We have demonstrated that human -defensin can
cause vasomotor dysfunction, increase superoxide anion
production, and decrease eNOS expression in porcine cor-
onary arteries. However, only human defensin at 1500 nM
had a detrimental effect on endothelial functions of porcine
coronary arteries. In the future, a large range of concentra-
tions of human defensin should be used to study its effects
on endothelium-dependent vasorelaxation, superoxide an-
ion production, and eNOS expression, thereby better indi-
cating clinical significance of defensins.
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